IDL Biotech AB takes a first step in introducing the rapid test for bladder cancer, UBC® Rapid, in the USA | IDL Biotech
IDL Biotech

CLOSE MENU

Articles

Bladder cancer

July 2019

IDL Biotech AB takes a first step in introducing the rapid test for bladder cancer, UBC® Rapid, in the USA

IDL Biotech has submitted supporting documents to the US FDA (Food and Drug Administration) to be able to obtain future approval of UBC® Rapid, the company's rapid test for bladder cancer.

Read the press release here (in swedish)

IDL Biotech förbereder kliniska studier i USA för sitt snabbtest för blåscancer, UBC® Rapid

Under 2019 lämnade IDL Biotech in underlag, en så kallad ”pre-submission request”, till amerikanska FDA (Food and Drug Administration) för att kunna få ett framtida godkännande av UBC® Rapid, bolagets snabbtest för blåscancer. Nu går bolaget vidare och förbereder kliniska studier i USA.

Business Development Manager Asia

IDL Biotech has appointed Subyung Park as Business Development Manager Asia with a focus on the product TUBEX® TF.

IDL Biotech

Skip this intro